Treatment of patients comorbid for addiction and other psychiatric disorders

被引：38
作者：
Brady K.T. [1 ]
Verduin M.L. [1 ]
Tolliver B.K. [1 ]
机构：
[1] Clinical Neuroscience Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29425
来源：
Current Psychiatry Reports | 2007年 / 9卷 / 5期
关键词：
Cocaine; Bipolar Disorder; Olanzapine; Personality Disorder; Aripiprazole;
D O I：
10.1007/s11920-007-0048-0
中图分类号：
学科分类号：
摘要：
Psychiatric disorders and drug and alcohol use disorders commonly co-occur. A growing literature has documented the epidemiology and effects on the course of illness of comorbid psychiatric and substance use disorders (SUDs). Advances in treatment of co-occurring illnesses have progressed more slowly. The current article reviews recent developments in the diagnosis and treatment of co-occurring psychiatric disorders and SUDs with particular focus on psychotic disorders, affective disorders, anxiety disorders, personality disorders, and attention-deficit/hyperactivity disorder. Current treatment options and implications for future research are highlighted. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：374 / 380
页数：6
相关论文
共 50 条
  • [1] Regier D.A., Farmer M.E., Rae D.S., Et al., Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study, JAMA, 264, pp. 2511-2518, (1990)
  • [2] Kessler R.C., McGonagle K.A., Zhao S., Et al., Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey, Arch Gen Psychiatry, 51, pp. 8-19, (1994)
  • [3] Conway K.P., Compton W., Stinson F.S., Grant B.F., Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions, J Clin Psychiatry, 67, pp. 247-257, (2006)
  • [4] Kessler R.C., Birnbaum H., Demler O., Et al., The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R), Biol Psychiatry, 58, pp. 668-676, (2005)
  • [5] Kessler R.C., Chiu W.T., Demler O., Et al., Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication, Arch Gen Psychiatry, 62, pp. 617-627, (2005)
  • [6] Swartz M.S., Wagner H.R., Swanson J.W., Et al., Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study, J Nerv Ment Dis, 194, pp. 164-172, (2006)
  • [7] Green A.I., Treatment of schizophrenia and comorbid substance abuse: Pharmacologic approaches, J Clin Psychiatry, 67, SUPPL. 7, pp. 31-35, (2006)
  • [8] Stuyt E.B., Sajbel T.A., Allen M.H., Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders, Am J Addict, 15, pp. 166-173, (2006)
  • [9] Petrakis I.L., Leslie D., Finney J.W., Rosenheck R., Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia, Am J Addict, 15, pp. 44-49, (2006)
  • [10] Brunette M.F., Drake R.E., Xie H., Et al., Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders, Schizophr Bull, 32, pp. 637-643, (2006)
12345